-$0.33 EPS Expected for Sangamo Therapeutics Inc (NASDAQ:SGMO) This Quarter

Equities analysts forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report earnings per share of ($0.33) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.18). Sangamo Therapeutics posted earnings per share of ($0.13) during the same quarter last year, which would suggest a negative year over year growth rate of 153.8%. The company is scheduled to report its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.71) to ($0.92). For the next fiscal year, analysts expect that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.88) to $0.05. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 28.97%. The company had revenue of $17.55 million for the quarter, compared to analyst estimates of $13.58 million. During the same quarter last year, the business earned ($0.17) earnings per share. Sangamo Therapeutics’s revenue was down 18.1% compared to the same quarter last year.

Several brokerages have commented on SGMO. ValuEngine upgraded shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the company a “hold” rating in a report on Monday, July 8th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. Finally, BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Four research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $13.33.

Shares of NASDAQ:SGMO traded up $0.21 during trading hours on Thursday, hitting $11.44. The stock had a trading volume of 1,164,052 shares, compared to its average volume of 2,072,304. The firm has a fifty day moving average price of $11.48. Sangamo Therapeutics has a 1-year low of $6.26 and a 1-year high of $19.25. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -16.34 and a beta of 2.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.98 and a quick ratio of 3.98.

In other news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of SGMO. Steward Partners Investment Advisory LLC bought a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $50,000. Tiverton Asset Management LLC bought a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $79,000. Pearl River Capital LLC bought a new position in Sangamo Therapeutics during the 1st quarter worth approximately $94,000. Oppenheimer Asset Management Inc. raised its holdings in Sangamo Therapeutics by 47.3% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,032 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 4,184 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC bought a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $126,000. Institutional investors and hedge funds own 57.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Story: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.